| First Author | Yin H | Year | 2024 |
| Journal | Cell Mol Immunol | Volume | 21 |
| Issue | 6 | Pages | 589-603 |
| PubMed ID | 38649449 | Mgi Jnum | J:360489 |
| Mgi Id | MGI:7797634 | Doi | 10.1038/s41423-024-01156-8 |
| Citation | Yin H, et al. (2024) Inhibition of METTL3 in macrophages provides protection against intestinal inflammation. Cell Mol Immunol 21(6):589-603 |
| abstractText | Inflammatory bowel disease (IBD) is prevalent, and no satisfactory therapeutic options are available because the mechanisms underlying its development are poorly understood. In this study, we discovered that increased expression of methyltransferase-like 3 (METTL3) in macrophages was correlated with the development of colitis and that depletion of METTL3 in macrophages protected mice against dextran sodium sulfate (DSS)-induced colitis. Mechanistic characterization indicated that METTL3 depletion increased the YTHDF3-mediated expression of phosphoglycolate phosphatase (PGP), which resulted in glucose metabolism reprogramming and the suppression of CD4+ T helper 1 (Th1) cell differentiation. Further analysis revealed that glucose metabolism contributed to the ability of METTL3 depletion to ameliorate colitis symptoms. In addition, we developed two potent small molecule METTL3 inhibitors, namely, F039-0002 and 7460-0250, that strongly ameliorated DSS-induced colitis. Overall, our study suggests that METTL3 plays crucial roles in the progression of colitis and highlights the potential of targeting METTL3 to attenuate intestinal inflammation for the treatment of colitis. |
